Back to search results

Study of GS-2426 for Advanced Solid Tumors

This study is testing a drug called GS-2426 in people with advanced solid tumors that have a specific genetic change called MTAP-deleted. The main goal is to understand how safe GS-2426 is and what side effects it might cause. Researchers also want to find the best dose to give. You might be able to join if you are 18 or older, have advanced solid tumors that are MTAP-deleted, and your current treatments are not working or you can't take them. The study will look at side effects and lab test changes for up to 105 weeks after your first dose.

Study design
This is an interventional study planning to enroll 174 participants. It is testing the drug GS-2426.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be monitored for side effects and lab abnormalities for up to 30 days after their last dose, which could be up to 105 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07601243

Study of GS-2426 in Participants With Advanced Solid Tumors

Recruiting
PHASE1Ages 18+InterventionalTreatment
Gilead Sciences
~174 participants
Updated 2026-08-03 on ClinicalTrials.gov
What's tested:GS-2426

At a glance

Recruiting sites
4 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAE)
Measured over First dose up to 30 days post last dose (up to 105 weeks)
+4 more outcomes measured

Conditions

Advanced Solid Tumors

Explore related trials

Solid NeoplasmMTAP Gene

NCT07601243

Where you'd take part

This study runs at 4 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Memorial Sloan Kettering Cancer Center

    New York, New Yorkno site contact published

    Recruiting

  • START Astera, LLC

    East Brunswick, New Jerseyno site contact published

    Recruiting

  • START Midwest

    Grand Rapids, Michiganno site contact published

    Recruiting

  • START San Antonio, LLC

    San Antonio, Texasno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Gilead Study Director · STUDY_DIRECTOR · Gilead Sciences

Who to contact

Gilead Clinical Study Information Center
[email protected]
1-833-445-3230 (GILEAD-0)
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants 18 years of age or older (≥ 19 years old for participants in South Korea).
Histologically or cytologically confirmed advanced malignant solid tumors, who have progressed on, are intolerant to or are ineligible for standard therapy, or have no standard treatment options.
Participant tumors are methylthioadenosine phosphorylase (MTAP)-deficient.
Adequate organ function
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
All participants must provide a pretreatment tumor tissue sample.

Exclusion

Participants with plans to breastfeed during the study period or within 7 days following the last dose of study intervention.
Have not recovered (ie, returned to Grade 1 or baseline) from clinically significant adverse events (AEs) due to a previously administered agent or a previous intervention as assessed by the investigator.
Active second malignancy. Individuals with a history of malignancy who have been completely treated with no evidence of active cancer for 5 years prior to enrollment, or individuals with surgically cured tumors with low risk of recurrence may be enrolled.
Requirement for ongoing therapy with any prohibited medications .
Prior therapy with a protein arginine methyltransferase 5 (PRMT5) inhibitor or methionine adenosine transferase 2a (MAT2A) inhibitor.
Have serious infection requiring antibiotics within 14 days prior to the first dose.
Uncontrolled concurrent diseases

What this trial measures

  • Percentage of Participants Experiencing Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAE)First dose up to 30 days post last dose (up to 105 weeks)
  • Percentage of Participants Experiencing Clinical Laboratory AbnormalitiesFirst dose up to 30 days post last dose (up to 105 weeks)
  • Percentage of Participants Experiencing Any Dose-limiting Toxicities (DLTs)First dose up to 21 days post first dose
  • Maximum Tolerated Dose (MTD)/Maximum Administered Dose (MAD)First dose up to 21 days post first dose
  • Recommended Phase 2 Dose (RP2D)Predose to end of study (up to 105 weeks)